Filing search / VYNE Therapeutics Inc. / "Recruit"

8-K

EX-99.2

VYNE VYNE Therapeutics Inc.

10 Nov 22

VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

4:16pm

acetylated histones, recruit transcription factors and release pro - inflammatory cytokines Pro - inflammatory cytokines inactive gene cytokine translation

8-K

EX-99.1

VYNE VYNE Therapeutics Inc.

10 Aug 22

VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

5:01pm

applications; VYNE’s ability to recruit and retain key employees; and VYNE’s ability to stay in compliance with applicable laws, rules and regulations

8-K

EX-99.1

VYNE VYNE Therapeutics Inc.

27 Jul 22

Regulation FD Disclosure

9:15am

by “reading” acetylated lysine motifs on N - terminus of histone tails and recruit co - regulatory complexes: How BET Proteins Influence Transcriptional … recognize acetylated histones & recruit transcription factors/form transcription complexes Pro - inflammatory cytokines inactive gene cytokine

8-K

EX-99.1

VYNE VYNE Therapeutics Inc.

17 Jun 22

VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

8:15am

; VYNE’s ability to recruit and retain key employees; and VYNE’s ability to stay in compliance with applicable laws, rules and regulations, including

8-K

EX-99.1

l9o6ydrq

17 May 22

Regulation FD Disclosure

10:01am

8-K

EX-99.1

160fiaga 6dam0

7 Apr 22

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

5:00pm

8-K

EX-99.1

560hmo5un3

30 Mar 22

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of

8:00am

8-K

EX-99.1

a88km0o8na6

17 Mar 22

VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update

8:00am

8-K

EX-99.1

ordw8m2gj65ht 6575f

7 Mar 22

VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo

7:00am

8-K

EX-99.1

xbnenx5 3tvv3oy6oxmr

19 Jan 22

VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

8:00am

8-K

EX-99.1

2tuoyv5my5vovpn2s

5 Jan 22

INVESTOR PRESENTATION January 2022

7:30am

8-K

EX-99.2

fxuzi7fprsns056ci0

10 Nov 21

VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

7:30am

8-K

EX-99.1

adgo9mq3c7s3xwr5xnb

4 Nov 21

Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study

8:35am

8-K

EX-99.1

pppbu

26 Oct 21

Other Events

8:16am

8-K

EX-99.1

kisj ml3s

19 Oct 21

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis

8:31am

8-K

EX-99.2

sjprsp

12 Aug 21

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning

8:36am

8-K

EX-99.3

f5e1i v99

12 Aug 21

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning

8:36am

8-K

EX-99.1

zdprsf gakxge

12 Aug 21

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning

8:36am

8-K

EX-99.1

6fl27tvkbx25

6 May 21

VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

7:10am